SEMA4D has been confirmed to be expressed at high levels in a variety of tumors, including prostate cancer, colon cancer, breast cancer, oral cancer, lung cancer, pancreatic cancer, head and neck carcinoma, and soft tissue sarcoma (2). Here, SEMA4D is linked to breast cancer.